| Ytd | -5.36% | |
| 1y | 107.11% |
| Open | 34.01 | Prev Close | 34.01 | Low | 32.92 | High | 34.31 | Mkt Cap | 3.82B |
| Vol | 798.36K | Avg Vol | 796.58K | EPS | -1.68 | P/E | N/A | Forward P/E | -25.23 |
| Beta | 0.13 | Short Ratio | 8.25 | Inst. Own | 106.28% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-07 | 50-d Avg | 32.71 | 200-d Avg | 31.05 | 1yr Est | 49.89 |
NAMS News
NewAmsterdam Pharma is advancing obicetrapib, an oral CETP inhibitor, targeting unmet LDL-C lowering
NAARDEN, the Netherlands and MIAMI, April 08, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N
NewAmsterdam Pharma (NASDAQ: NAMS - Get Free Report) and Shineco (NASDAQ: SISI - Get Free Report) ar
Aberdeen Group plc grew its holdings in NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS) by 10.2% dur
NAARDEN, the Netherlands and MIAMI, April 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N
NAARDEN, The Netherlands and MIAMI, March 23, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS - Get Free Report) insider Johannes Jacob Piete Kaste
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS - Get Free Report) insider Johannes Jacob Piete Kaste
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS - Get Free Report) insider Johannes Jacob Piete Kaste
NAARDEN, the Netherlands and MIAMI, March 06, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS - Get Free Report) CEO Michael Davidson sold 183,332
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS - Get Free Report) insider Johannes Jacob Piete Kaste
NAARDEN, the Netherlands and MIAMI, Feb. 25, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.
Guggenheim analyst Debjit Chattopadhyay maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy
Needham analyst Serge Belanger maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy and rais
-- Approval decisions from EMA, UK and Switzerland regulators for obicetrapib and obicetrapib/ezetim
NewAmsterdam Pharma (NASDAQ: NAMS) Chief Financial Officer Ian Somaiya said the company remains enco
NAARDEN, The Netherlands and MIAMI, Feb. 06, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.
NAARDEN, The Netherlands and MIAMI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS - Get Free Report) CAO Louise Frederika Kooij sold 34
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS - Get Free Report) CAO Louise Frederika Kooij sold 38
RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Outperf
-- EMA approval decision for obicetrapib and obicetrapib/ezetimibe fixed dose combo expected in 2H26
-- EMA approval decision for obicetrapib and obicetrapib/ezetimibe fixed dose combo expected in 2H26
Stifel analyst James Condulis maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy and raise
Goldman Sachs analyst Asad Haider maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Neutral
RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Outperf
Needham analyst Serge Belanger maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy and rais
NewAmsterdam Pharma (NASDAQ:NAMS) reported quarterly losses of $(0.61) per share which missed the an
HC Wainwright & Co. analyst Joseph Pantginis assumes NewAmsterdam Pharma Co (NASDAQ:NAMS) wit
Citigroup analyst Geoff Meacham maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy and rai
Wells Fargo analyst Yanan Zhu initiates coverage on NewAmsterdam Pharma Co (NASDAQ:NAMS) with a O
The multi-million-dollar investment provides NewAmsterdam Pharma with commercial capacity for fixed
RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Outperf
NewAmsterdam Pharma (NASDAQ:NAMS) reported quarterly losses of $(0.15) per share which beat the anal
-- Pre-specified analysis shows obicetrapib significantly reduced absolute levels of plasma p-tau217
https://www.statnews.com/2025/07/30/new-amsterdam-pharma-cholesterol-drug-alzheimers/
Goldman Sachs analyst Asad Haider initiates coverage on NewAmsterdam Pharma Co (NASDAQ:NAMS) wit
Citigroup analyst Geoff Meacham initiates coverage on NewAmsterdam Pharma Co (NASDAQ:NAMS) with a
Needham analyst Serge Belanger reiterates NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy and mai
Stifel analyst James Condulis initiates coverage on NewAmsterdam Pharma Co (NASDAQ:NAMS) with a B
NewAmsterdam shared new Phase 3 data showing obicetrapib reduced LDL-C by 33% and impacted Alzheimer
Pre-specified analyses show that obicetrapib treatment leads to statistically significant and clinic
